|
Multiple Myeloma
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
One of these (rs3777189-C) co-locates with the best-supported lead variants for ELL2 expression and MM risk, and reduces binding of MAFF/G/K family transcription factors.
|
29695719 |
2018 |
|
Multiple Myeloma
|
0.130 |
AlteredExpression
|
disease |
BEFREE |
Since ELL2 is critical to the B cell differentiation process, reduced ELL2 expression is consistent with inherited genetic variation contributing to arrest of plasma cell development, facilitating MM clonal expansion.
|
28903037 |
2017 |
|
Multiple Myeloma
|
0.130 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.
|
28112199 |
2017 |
|
Multiple Myeloma
|
0.130 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.
|
27363682 |
2016 |
|
Multiple Myeloma
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
We find that the MM risk allele harbours a Thr298Ala missense variant in an ELL2 domain required for transcription elongation.
|
26007630 |
2015 |
|
Multiple Myeloma
|
0.130 |
GeneticVariation
|
disease |
GWASCAT |
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
|
26007630 |
2015 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.
|
28112199 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.
|
28112199 |
2017 |
|
Small Lymphocytic Lymphoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.
|
28112199 |
2017 |
|
Monoclonal Gammopathy of Undetermined Significance
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
|
26007630 |
2015 |
|
Paraproteinemias
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
|
26007630 |
2015 |
|
Serum total protein measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Discovery and fine mapping of serum protein loci through transethnic meta-analysis.
|
23022100 |
2012 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
ELL2 knockdown enhanced prostate cancer cell proliferation and motility.
|
30009504 |
2018 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
Here, knockdown of ELL2 sensitized prostate cancer cells to DNA damage and overexpression of ELL2 protected prostate cancer cells from DNA damage.
|
29179998 |
2018 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Here, knockdown of ELL2 sensitized prostate cancer cells to DNA damage and overexpression of ELL2 protected prostate cancer cells from DNA damage.
|
29179998 |
2018 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
ELL2 knockdown enhanced prostate cancer cell proliferation and motility.
|
30009504 |
2018 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
We recently showed that ELL2 loss could enhance prostate cancer cell proliferation and migration, and that <i>ELL2</i> gene expression was downregulated in high Gleason score prostate cancer specimens.
|
28870994 |
2017 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
ELL2 expression in human prostate cancer specimens was detected using quantitative polymerase chain reaction coupled with laser capture microdissection.
|
28167296 |
2017 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
ELL2 expression in human prostate cancer specimens was detected using quantitative polymerase chain reaction coupled with laser capture microdissection.
|
28167296 |
2017 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We recently showed that ELL2 loss could enhance prostate cancer cell proliferation and migration, and that <i>ELL2</i> gene expression was downregulated in high Gleason score prostate cancer specimens.
|
28870994 |
2017 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Immunostaining analysis of human prostate cancer specimens was used to determine ELL2 expression in tumor and normal tissues.
|
30009504 |
2018 |
|
Prostatic Intraepithelial Neoplasias
|
0.020 |
Biomarker
|
disease |
BEFREE |
Deletion of Ell2 in the murine prostate induced murine prostatic intraepithelial neoplasia and ELL2 knockdown enhanced proliferation and migration in C4-2 prostate cancer cells.
|
29179998 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our results provide the first evidence that ELL2 is a direct target of miR-299 and increased ELL2 expression and down-regulation of miR-299 are associated with GBM progression and poor prognosis in patients, suggesting that ELL2 and miR-299 might have potential prognostic value and be used as tumor biomarkers for the diagnosis of patients with GBM.
|
28531325 |
2017 |
|
Prostatic Intraepithelial Neoplasias
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, prostate-specific deletion of ELL2 in a mouse model revealed a potential role for ELL2 as a prostate tumor suppressor <i>in vivo</i><i>Ell2</i>-knockout mice exhibited prostatic defects including increased epithelial proliferation, vascularity and PIN lesions similar to the previously determined prostate phenotype in <i>Eaf2</i>-knockout mice.
|
28870994 |
2017 |